The collection of red blood cells (RBC) by apheresis, first developed in the 1970's for therapeutic use, for many years was not considered suitable for obtaining blood components for transfusion because of concerns on donor safety and elevated costs compared to whole blood (WB) donation. Single-dose RBC apheresis as a part of multicomponent collections and double-dose RBC (2RBC) apheresis for autologous and allogeneic transfusions were approved by the FDA between 1995 and 1997, and in Europe starting from 2000. The widespread implementation of these procedures followed mainly to address blood supply issues, as large numbers of blood components can be rapidly obtained. However, this potential advantage has been only partially confirmed in real practice, with striking regional differences. Limitations of 2RBC collections regarding both blood supply and donor safety have emerged. In particular, donor motivation, iron deficiency and risk of anaemia are issues that need to be addressed. On the other side, 2RBC apheresis represents a valuable alternative to WB collection for autologous or dedicated donations, can reduce the risk of alloimmunization in chronically transfused patients and can facilitate transfusion support in specific cases (i.e. patients with multiple alloantibodies or rare blood groups). Reducing patient exposure to different donors can also be relevant for preventing the transmission of blood-borne infections.
Introduction
Automated red blood cell (RBC) collections are performed for both therapeutic and preparative purposes. In blood donors, RBC components can be obtained as a part of multicomponent apheresis or double-dose RBC (2RBC) donations. Thanks to the development of new collection systems, and as demonstrated by experience, today, RBC apheresis is considered safe for the donor, although particular care is given to the selection of subjects who are suitable for these procedures.
The necessity of assuring sufficiency for RBC components was the principal reason that initially led to the implementation of 2RBC collections in many countries, but in the recent decade, the opposite trends are being observed in different parts of the world.
In the last years, the most significant changes in transfusion medicine concern the more difficult recruitment and motivation of healthy volunteers for blood donation due to socio-demographic developments, the overall decreasing usage of RBC transfusions mainly because of the widespread adoption of Patient Blood Management programs and the overall increasing number of patients receiving regular transfusions thanks to the broader availability of medical care and longer life expectancy.
In this review, advantages and drawbacks of RBC apheresis (summarized in Table 1 ) will be discussed, focusing in particular on the role of 2RBC collections in assuring sufficiency, and the implications of this type of donation for the blood donor and for the recipients of transfusions.
MCS+, the Trima and the ALYX. With all systems, predefined absolute RBC volumes with small variations are obtained [1, 2] . With 2RBC procedures, cell volumes of 360, 400 or 420 ml can be collected that are then manually divided into two single-dose units.
For the blood donation staff, the workload for multicomponent and 2RBC aphereses is overall greater than that for whole blood (WB) collections, because scheduling the donations and performing the procedures are more time-consuming and the whole donation process is more cost intensive. The mean duration of a 2RBC procedure is about 33 min with the MCS+ and 26 min with the Trima for obtaining 420 and 400 ml RBC, respectively [3] , and 25 min with the ALYX for collecting 360 ml RBC [4] . Importantly, also the recruitment of 2RBC donors is more difficult due to the specific selection criteria required, as discussed below. Moreover, although frequently done by many institutions, mainly in the United States, logistic problems (transport of the device, longer time needed for a single donation, turnaround time for staff and donors and organization of workflow) can limit the feasibility of 2RBC collections at mobile donation sites.
On the contrary, for manufacturing and laboratory testing, 2RBC collections are associated with reduced workload and costs, as no postdonation processing is required and testing is carried out only once for two therapeutic RBC units. In 2RBC apheresis, leucocyte removal by filtration is performed in-line during or at the end of the procedure, and the collected cell volume is distributed in two storage bags of equal weight automatically. As no further manipulation is needed, no RBC loss occurs. However, a disadvantage of 2RBC collections is that no plasma units and buffy coats for the manufacturing of platelet products can be obtained, as these components are returned to the donor. This limitation can be important depending on the short-term needs for specific blood products, but blood collection centres performing 2RBC apheresis can schedule 2RBC or WB collections according to component-specific or time-bound demands. For example, more 2RBC donations of selected blood groups (i.e. O negative) can be planned before holiday periods or in case of particular threads for RBC procurement (i.e. flu epidemics); conversely, more WB collections can be targeted, if buffy coat units for the production of platelet components are needed [1, 5] . As a further disadvantage, in case of a true or unspecific positive screening test in a 2RBC donor or following postdonation information, two RBC units have to be discarded.
Because an absolute specified RBC volume is obtained, independently of the donor's haematocrit, RBC units from apheresis have more consistent haemoglobin (Hb) levels, RBC mass and haematocrit compared to those from WB donations [3, 6] . The higher standardization of automatically collected RBC units is also of advantage for the applications of Good Manufacturing Practices due to a better process control in all steps of component production [6] . Published data demonstrated very good in vitro quality of single-dose and 2RBC products obtained with all collection systems and full compliance with regulatory requirements [7] . Notably, with respect to some storage parameters (ATP and 2-3 DPG content, extent of haemolysis, amount of free K+ and free Hb) and rheology characteristics, a better quality of automatically collected RBC components was reported compared to those from WB collections [8, 9] . A possible explanation for this qualitative difference is the continuous and uniform mixing of the cells with the anticoagulant that occurs during apheresis, with a more constant anticoagulant to RBC ratio, which reduces the lesion of collection of RBC [3, 8] .
RBC apheresis from the perspective of the blood donor
For the blood donor, but also for the blood collection centre, the principal advantage of donating 2RBC by apheresis is that a maximal contribution to blood supply with less visits is provided. Aiming to reduce risks for adverse events (AEs) and iron depletion (ID), more stringent criteria regarding total blood volume (TBV) and Hb cut-offs are applied for the selection of 2RBC donors, who are also allowed to donate less frequently than WB donors. The Council of Europe requires a TBV of ≥ 4Á5 l (estimated on gender, height and weight) and a minimal predonation Hb level ≥ 140 g/l; the maximal RBC volume to be collected varies according to gender, TBV and Hb level and must not exceed 400 ml; the minimal interval between two 2RBC aphereses is 6 and 4 months for women and men, respectively. Monitoring of iron stores is recommended for 2RBC donors providing more RBC volume/year than that allowed for WB donations [10] . In comparison, the criteria of the American Red Cross, although similar regarding minimal lower TBV limits and Hb levels, allow a shorter interdonation interval [11] (Table 2) .
Complications of blood donation and ID have a negative impact on donor retention [12] , and significant ID occurs specifically after 2RBC apheresis. Studies on AEs in large cohorts of 2RBC donors describe overall a lower incidence of complications compared to WB donations and a very low incidence of severe AEs [13] [14] [15] [16] [17] . Importantly, in 2RBC donation, volume replacement with saline is generally recommended and often performed. Moreover, the larger body mass and blood volume of donors, and the smaller amount of citrate reinfused and the shorter duration of the procedure compared to plasma or platelet collections reduce citrate toxicity. If also minor reactions and postdonation fatigue are considered, however, actually AEs are more frequent in 2RBC than in WB collections [15, 16] . In our experience, 5% of 641 subjects who abandoned 2RBC donation indicated AEs as a reason, with fatigue being the most frequent symptom reported [4] . This complication can significantly impair physical activity in the days following the donation, and 2RBC donors with professions or hobbies requiring high physical performance should be informed on this possible side-effect. In some centres, for instance, endurance athletes are often advised to avoid 2RBC donations during training. Fatigue is also a consequence of WB donation [18] and may reflect a transitory situation of tissue ID or 'relative' anaemia [19, 20] that can be more substantial after 2RBC apheresis.
ID occurs inevitably with 2RBC donation [21] [22] [23] [24] , but anaemia can be prevented by iron supplementation [22, 24, 25 ]. However, not many studies have specifically focused on ID in 2RBC donors, and published data are difficult to compare because of different donor selection criteria, the type of device used, collection volumes and intervals. RBC volume removed and interdonation interval are probably the most important factors in determining the risk of ID anaemia for the donor. A differentiated RBC volume collection according to gender, TBV and Hb level was recommended for donor safety [26] . An interval of approximately 4 months, as currently allowed for men in Europe and for both genders in North America, appears to be adequate for the recovery of red cells but not of iron stores, if no iron supplementation is given [21] . At our centre, the majority of 2RBC males who donated 2RBC more than five times without receiving iron supplementation had serum ferritin levels in the lower normal range (50-70 lg/l, with reference values for males being 30-300 lg/l), but did not develop anaemia even after many consecutive aphereses (unpublished data). These findings can be explained with the longer interdonation interval (6 months) and the lower RBC volume collected (360 ml) required by the Swiss directives [27] . Due to this protective approach, in Switzerland, the maximal number of RBC units/year that can be obtained from male donors is the same with both 2RBC apheresis and WB donation, a fact that reduces the advantage of 2RBC collections for RBC procurement. However, if a higher 2RBC donation frequency allows the obtainment of a larger number of RBC units, it also increases the risk of ID anaemia that can lead to a loss of experienced donors and negatively impact the blood supply in the long term [12] On the other hand, asymptomatic carriers of hereditary haemochromatosis, if allowed to donate blood, benefit particularly from 2RBC apheresis, as a large amount of iron is removed with one procedure and stable iron levels can be maintained by regular 2RBC donation [28] . Table 3 shows procedure-related data of 2RBC apheresis relevant for the risks of AEs and ID in blood donors. Data concern 291 donations performed with the ALYX, with a RBC collection volume of 360 ml (adapted from Keshelashvili et al. [4] ). For comparison, at our centre, the mean citrate volume reinfused in a single-and double-dose platelet apheresis with the Amicus is 264 and 362 ml, respectively.
As a result of the combination of practical aspects and donor-related issues, retention of 2RBC donors is lower compared to that of WB donors [3, 4] . Restrictive eligibility criteria, AEs, lack of motivation due to longer interdonation intervals, scarce availability of 2RBC apheresis on mobile donation sites and inconvenience because of time issues, along with the ongoing socio-demographic changes of the donor base and psychologic factors [29, 30] , are reasons described for the overall lower commitment towards 2RBC donation.
The role of RBC apheresis for blood supply
Overall, the notion that 2RBC apheresis substantially contributes to RBC procurement, as theoretically expected, is only partially confirmed by experience, but it is important to stress that remarkable differences are observed among countries and institutions.
In Europe, automated RBC collections are carried out in 16 of 47 countries responding to the 2013 EDQM survey, which indicates RBC apheresis of being of particular interest for autologous programmes and for obtaining RBC units of rare blood types [31] . In 2011-2012, the number of RBC units from apheresis in Europe was 25 800 compared to the 1Á9 million components collected in AABB member centres [32] . In Iceland, the European country performing the largest number of 2RBC aphereses, automatically collected RBC units represented only 1Á7% of the total RBC production [31], while in the same period, 13Á8% of all collected RBC components for allogenic transfusion were apheresis-derived in AABB member institutions [32] . In Europe, 2RBC aphereses for both autologous and allogeneic use are constantly decreasing. For example, in Germany, the number of RBC units . On the contrary, the trend of automated RBC collections in AABB centres is continuously rising in the last years. In the period 2011-2013, the number of RBC aphereses for autologous use increased by 75% (from 4000 to 7000) and the percentage of apheresis-derived RBC units for allogeneic transfusion also increased, although a drop of 5Á6% in the absolute number of procedures was observed [32] . This development is explained by the increasing selective collection of O-negative RBC by apheresis in response to the increasing demand of such units for transfusion. The restricted RBC apheresis activity in Europe can be explained with an overall low acceptance of the procedure by the donors, for the reasons discussed above, and because in general, no particular sufficiency issues are perceived that would be addressed by 2RBC collections. The latter explains also why some European countries, such as the UK and Ireland, but also Australia and New Zealand, chose not to implement 2RBC apheresis. The success of 2RBC donations in North America is possibly due to the greater effort made on the part of blood collection institutions in recruiting suitable blood donors, in order to enhance the average number of blood products donated/donor/year, which is generally lower compared to Europe.
RBC apheresis from the perspective of the recipient of RBC transfusions
For the patient requiring transfusions, receiving two RBC units from the same donor potentially reduces the risks for alloimmunization and blood-borne infections because of the restricted exposition to different allogeneic RBC products. This is of relevance both if RBC units are regularly needed over time and for one-time transfusions (i.e. predicted or unexpected blood loss during surgery or at delivery), and in the latter case, the benefits of a limited exposure to different donors are particularly important if the patient is a child or adolescent or a young female.
In chronically transfused patients, the incidence of alloimmunization increases with the number of units received, being particularly elevated in sickle cell disease (18-47%) [34, 35] and thalassaemia major (2-30%) [36] . However, the advantage of 2RBC collections in this setting may be overcome by the large number of RBC units required by the patients over time. Importantly, RBC antigen disparity between donors and recipients of transfusions represents per se a significant risk for the development of alloantibodies [35, 37, 38] , as is the case for patients with haemoglobinopathies who live in Europe or North America, is frequently of African or Asian origin and receive mostly RBC units from Caucasian donors. Targeting a broader RBC antigen matching beyond ABO and Rh phenotype can prevent alloimmunization [39, 40] . To this purpose, specifically promoting 2RBC donation in the recruitment of blood donors of African and Asian origin, which can be however a rather challenging task [41] , would be a winning approach for ensuring an optimal support for many chronically transfused patients. Similarly, also in subjects with haematological diseases and multiple alloantibodies, the availability of 2RBC apheresis increases flexibility for the blood banks in addressing specific requirements. Identifying a group of regular, dedicated 2RBC donors would be the ideal approach in several situations where transfusion support is difficult. However, if only a small number of compatible 2RBC donors are found for a given patient, but transfusions are regularly needed, WB collections can be more convenient, because of the shorter interdonation interval and the larger number of eligible subjects available. Alternatively, 2RBC products can be manually split into low volume units or in up to eight paediatric components. For many patients, such highly standardized RBC units would allow a sufficient Hb increase and reduce donor exposure for the patient at the same time. A further advantage of automatically collected RBC units for the recipient of chronical transfusions is that the higher consistency in volume and Hb content can result in a more constant rise of Hb in the patient and possibly reduce transfusion requirements [42] .
In case of multiple alloantibodies or rare blood group, if a one-time transfusion only is required and dedicated donors are scarce or not available, an autologous 2RBC collection can be considered, provided that the patient is in good clinical condition and Hb levels are sufficient. Although autologous transfusions are overall declining, autologous 2RBC collections can be of value in specific cases and in the context of Patient Blood Management programs. However, in real life, only a limited number of patients are likely to be eligible for such procedures, because of comorbidities, age, peripheral venous access and Hb levels.
Reducing the risks of transfusion-transmitted diseases through limiting patient exposure to different donors can be of great advantage in regions with high prevalence of infections, such as malaria and hepatitis B, or during outbreaks. In this situation, besides enhancing RBC procurement from healthy subjects, 2RBC collections could rapidly provide components to be treated with pathogen reduction methods.
Conclusions
Double-dose RBC apheresis provides high-quality RBC components and saves costs for manufacturing and laboratory testing. The procedure is safe for the blood donor, but recruitment and retention of eligible subjects are generally difficult. Still open issues are the influence of iron loss and minor AEs on donor retention. Optimal strategies for protecting the blood donor and at the same time enhancing commitment for 2RBC donations are still needed. 2RBC are a valuable option for asymptomatic carriers of haemochromatosis who can be accepted for blood donation.
For the blood supply in general, the role of 2RBC collections appears to be less relevant as initially expected, but great regional differences are observed. Sufficiency may not be a major issue in countries with well-established blood donation programmes, where also a constant drop in the usage of RBC components is observed [31, 32] . However, increased demands of RBC units of specific blood groups on one side and the shrinking of the blood donor base on the other side represent recurrent shorttime challenges and a problem in the medium-to-long term, respectively. In countries where blood donation services are developing and/or the donor base is more limited, obtaining RBC units rapidly is of utmost importance and 2RBC collections can increase procurement efficiency.
Supplying RBC units of specific type to patients with alloantibodies and/or requiring chronical transfusions often represents a challenging task for blood banks in all countries. Also in these cases, 2RBC apheresis has a definite role, although advantages can be limited by practical aspects and by the availability of good matched blood donors. A possible strategy is the establishment of groups of dedicated 2RBC donors for single patients. Moreover, pathogen reduction treatment of automatically collected RBC units could be of great advantage in case of timerestricted or endemic infectious treats.
